Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study)

Table 4

Changes in residual urine volume and QT interval in the short-term analysis set.

Variable		Imidafenacin	Solifenacin
Number of subjects		17	18
Residual urine volume (mL)
0 week	(Mean ± SD)	14.2±15.1	13.5±11.4
4 week	(Mean ± SD)	29.3±26.2^∗∗	40.8±33.2^∗∗	NS
12 week	(Mean ± SD)	37.7±32.7^∗∗	29.4±28.1^∗	NS
QT interval (ms)
0 week	(Mean ± SD)	414.8±20.7	423.2±21.8
4 week	(Mean ± SD)	415.5±16.5	423.5±19.0	NS
12 week	(Mean ± SD)	415.0±16.4	423.6±23.5	NS

Intragroup (versus 0 weeks: the end of the observation period)
Paired t-test *: 𝑃<0.05, **: 𝑃<0.01
Intergroup: unpaired t-test, NS: not significant, SD: standard deviation.